Hrishikesh Iyengar, MD
Interventional Cardiology · Salem, ORNPI 1861695165
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Novartis at 34.0% of the total. That places this record below the midpoint for interventional cardiology clinicians in OR, where the typical reported total is $4,729.
Across 241 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Medtronic$575
- Pfizer$565
- Boston Scientific$324
- Amgen$244
- Johnson & Johnson$192
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,723100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 101 | $1,607 |
| Medtronic | 8 | $575 |
| Pfizer | 33 | $565 |
| Boston Scientific | 11 | $324 |
| Amgen | 8 | $244 |
| Johnson & Johnson | 13 | $192 |
| E.r. Squibb & Sons, L.L.C. | 7 | $132 |
| Boehringer Ingelheim | 6 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $107 |
| Merck | 4 | $88 |
| AstraZeneca | 5 | $75 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| Abbott | 2 | $64 |
| Amarin Pharma, Inc. | 3 | $63 |
| Impulse Dynamics (USA) Inc. | 1 | $58 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Atricure, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Irhythm Technologies, Inc. | 2 | $32 |
| Penumbra, Inc. | 2 | $31 |
| Bardy Diagnostics, Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Bayer | 1 | $24 |
| Aegerion Pharmaceuticals, Inc. | 2 | $23 |
| Chiesi USA, Inc. | 1 | $20 |
| Terumo Medical Corporation | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
| Opsens Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$294
- GENERAL VASCULAR ACCESS$125
- Repatha$125
- Azure$114
How this compares
$4,729 in reported general payments places this provider in the 50th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 674 | $631,298 |
| EntrestoSacubitril/Valsartan | 107 | $131,369 |
| Repatha SureclickEvolocumab | 148 | $92,424 |
| XareltoRivaroxaban | 66 | $73,220 |
| Praluent PenAlirocumab | 30 | $17,906 |
| Atorvastatin Calcium | 737 | $10,109 |
| Metoprolol Succinate | 411 | $6,407 |
| Losartan Potassium | 262 | $2,882 |
| Disopyramide Phosphate | 13 | $2,805 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 93 | $2,494 |
| ClopidogrelClopidogrel Bisulfate | 158 | $1,955 |
| Carvedilol | 216 | $1,759 |
| Ezetimibe | 74 | $1,720 |
| Rosuvastatin Calcium | 123 | $1,461 |
| Flecainide Acetate | 57 | $1,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $565 | $631,298674 claims |
| NovartisEntresto | $1,607 | $131,369107 claims |
| Johnson & JohnsonXarelto | $192 | $73,22066 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Salem
- Kevin ThompsonSalem$56K
- Barath KrishnamurthySalem$7K
- Norman AiadSalem$3K
- Michael SchiedlerSalem$1K
- Jason WollmuthPortland$749K
- Saurabh GuptaBend$550K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
- Harsh GolwalaPortland$105K
- Brandon JonesPortland$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.